Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ko, MD
Han Seok Ko, Lutherville Timonium, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20120122958 | TRANSCRIPTIONAL REPRESSION LEADING TO PARKINSON'S DISEASE - Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1α and the PGC-1α target gene, NRF-1 by binding to insulin response sequences in the PGC-1α promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1α co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation. | 05-17-2012 |
Harvey W. Ko, Ellicott City, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080254502 | Method and Apparatus for Detection of Bioaerosols - A method and apparatus for evaluating a bioaerosol sample is provided which includes detecting frequency and/or time resolution factors that allow discriminate between a plurality of signals emitted by the bioaerosol to selectively detect biological materials contained in the bioaerosol sample from materials of non-biological origin and potentially associated with a pathogenic bioaerosol. | 10-16-2008 |
| 20110049390 | Method and Apparatus for Detection of Bioaerosols - A method and apparatus for evaluating a bioaerosol sample is provided which includes detecting frequency and/or time resolution factors that allow discriminate between a plurality of signals emitted by the bioaerosol to selectively detect biological materials contained in the bioaerosol sample from materials of non-biological origin and potentially associated with a pathogenic bioaerosol. | 03-03-2011 |
Minoru S.h. Ko, Cockeysville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20110014204 | Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2 - The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents. | 01-20-2011 |
Minoru S. H. Ko, Cockeysville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100105043 | METHODS FOR MODULATING EMBRYONIC STEM CELL DIFFERENTIATION - Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters. | 04-29-2010 |
Young Hee Ko, Owings Mills, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090326068 | Therapeutics for Cancer using 3-Bromopyruvate and other Selective Inhibitors of ATP Production - The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention. | 12-31-2009 |
| 20100197612 | Composition and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 08-05-2010 |
| 20100221220 | THERAPEUTICS FOR CANCER USING 3-BROMOPYRUVATE AND OTHER SELECTIVE INHIBITORS OF ATP PRODUCTION - The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention. | 09-02-2010 |
| 20110008418 | Compositions and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 01-13-2011 |